Unigestion Holding SA Trims Stake in Amgen Inc. (NASDAQ:AMGN)

Unigestion Holding SA cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 9.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,079 shares of the medical research company's stock after selling 1,692 shares during the quarter. Unigestion Holding SA's holdings in Amgen were worth $5,321,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of AMGN. Capital World Investors grew its holdings in Amgen by 1,292.0% in the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock valued at $1,693,042,000 after buying an additional 6,029,058 shares in the last quarter. Norges Bank acquired a new position in Amgen in the 4th quarter valued at about $1,541,991,000. GAMMA Investing LLC grew its stake in shares of Amgen by 43,573.5% in the 1st quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company's stock valued at $1,140,768,000 after buying an additional 3,653,205 shares during the period. Capital International Investors increased its holdings in shares of Amgen by 40.1% during the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock worth $3,182,843,000 after buying an additional 3,495,503 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Amgen by 25.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock valued at $3,441,909,000 after buying an additional 2,672,975 shares during the period. Hedge funds and other institutional investors own 76.50% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Cantor Fitzgerald started coverage on Amgen in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 target price for the company. Guggenheim started coverage on Amgen in a research report on Tuesday, May 20th. They set a "neutral" rating and a $288.00 price objective for the company. Wall Street Zen raised shares of Amgen from a "buy" rating to a "strong-buy" rating in a research note on Sunday, May 18th. Royal Bank of Canada reduced their price target on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Finally, Piper Sandler dropped their target price on shares of Amgen from $329.00 to $328.00 and set an "overweight" rating for the company in a report on Friday, May 16th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $309.22.

Amgen Stock Up 0.0%

Shares of NASDAQ AMGN traded up $0.09 during midday trading on Thursday, hitting $287.10. 2,519,578 shares of the company's stock were exchanged, compared to its average volume of 2,805,490. The firm's fifty day simple moving average is $282.39 and its 200-day simple moving average is $285.31. The company has a market cap of $154.38 billion, a PE ratio of 38.03, a P/E/G ratio of 2.63 and a beta of 0.51. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating the consensus estimate of $4.18 by $0.72. The company had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm's revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm posted $3.96 earnings per share. Research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.